Overview

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Status:
Not yet recruiting

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
Ciprofloxacin
Folfirinox
Metronidazole
Pembrolizumab